Search

In order to evaluate the safety and probiotic properties of Lactobacillus plantarum HCS03-001(CGMCC No.16258), the safety of Lactobacillus plantarum HCS03-001 was evaluated by hemolysis test, drug resistance test and acute transoral toxicity test. The probiotic properties of the strain were evaluated by acid and bile salt tolerance test, bacteriostatic functional properties test and laxative efficacy test. The results showed that Lactobacillus plantarum HCS03-001 did not form transparent circle on the Colombian blood finger culture medium, that was, there was no hemolysis. Lactobacillus plantarum HCS03-001 was sensitive to penicillin (PEN), ampicillin (AM), imipenem (IP), meropenem (MP), linezolid (LZ), and datoramycin (DPC), and neutral to erythromycin (EM) and resistant to vancomycin (VA). The acute oral toxicology of mice was non-toxic, and the strain was confirmed to be safe to eat.The survival rate of the strain was 94.29% and 92.33% at pH3.0 and pH2.0 for 3 h, respectively. The survival rate could still reach 88.82% at 1.5 g/L bile salt for 3 h. It had inhibitory effect on intestinal and oral pathogens (Porphyromonas gingivalis and Streptococcus mutans). It had a good effect on promoting defecation in constipation model of loperamide hydrochloride. Lactobacillus plantarum HCS03-001 has good safety and probiotics.

Objective To investigate the influencing factors for ribavirin (RBV)-induced hemolytic anemia during the treatment of chronic hepatitis C using RBV combined with pegylated interferon-α (PEG-IFNα), and to provide a reference for early prediction of RBV-related hemolytic anemia in clinical practice. Methods A total of 235 patients with chronic hepatitis C who were given antiviral therapy with PEG-IFNα combined with RBV in Beijing YouAn Hospital from March 2016 to March 2018 were enrolled. Parameters of routine blood test, liver function parameters, liver stiffness measurement, HCV RNA, HCV viral genotype, and inosine triphosphate pyrophosphatase (ITPA) genotype were determined before the antiviral therapy, and routine blood tests were performed at weeks 2, 4, 8, and 12 of treatment. The t-test was used for comparison of normally distributed continuous data between groups, and the Mann-Whitney U test was used for non-normally distributed continuous data between groups; the chi-square test or the Fisher’s exact test was used for comparison of categorical data between groups. Univariate analysis and multivariate logistic regression analyses were used to determine the influencing factors for RBV-related hemolytic anemia, and a predictive model was established accordingly; the receiver operating characteristic curve was used to analyze the predictive value of this model for RBV-related hemolytic anemia. Results At weeks 2, 4, 8, and 12 of treatment, the ITPA (rs1127354) genotype CC group had a significantly greater reduction in hemoglobin (Hb) than the ITPA (rs1127354) genotype AA+AC group (all P＜0.05). At week 4 of treatment, there was a significant difference between the AA+AC group and the CC group in the proportion of patients with a ＞30 g/L reduction in Hb (2.38% vs 39.9%, χ2=23.175, P＜0.001) or an Hb level of ＜100 g/L (0 vs 10.88%, P=0.018). The degree of reduction in Hb at week 2 (odds ratio (OR)=1.073, P＜0.001), ITPA (rs1127354) genotype (OR=18.920, P=0.005), and baseline Hb level (OR=1.032, P=0.024) were independent risk factors for a ＞30 g/L reduction in Hb at week 4. Conclusion Patients with ITPA (rs1127354) genotype CC tend to develop RBV-related hemolytic anemia. ITPA (rs1127354) genotype, baseline Hb level, and degree of reduction in Hb at week 2 can be used to predict the development of RBV-related hemolysis during anti-HCV treatment, in order to achieve early warning and guide early intervention. [ABSTRACT FROM AUTHOR]